Supplementary Material

Selectivity mechanism of BCL-XL/2 inhibition through in silico

investigation

Jiasi Luan^{a,b,c}, Baichun Hu^{a,b,d}, Shizhun Wang^{a,b,e}, Haihan Liu^{a,b,e}, Shuaizhong Lu^{a,b,e}, Weixia Li^{a,b,e}, Xizhe Sun^d, Jiyue Shi^{a,b,e}, Jian Wang^{a,b,e*}

a Key Laboratory of Structure-Based Drug Design &Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China b Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang 110016, China c School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China d School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's

Republic of China e School of Pharmaceutical Engineering Shenyang Pharmaceutical University Shenyang

e School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China

Corresponding author: Prof. Jian Wang, E-mail: jianwang@syphu.edu.cn.




Figure S1 Comparison of proteins and inhibitors. (A) Structures of BCL-XL and BCL-2 inhibitors. (B)Ligand interaction diagram.